ClinicalTrials.gg
CompletedNCT01263353COOPERATE-1Updated Dec 21, 2020

Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs

A Phase 1 interventional study of Pasireotide LAR followed by Pasireotide LAR + Everolimus and Everolimus followed by Pasireotide LAR + Everolimus in Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System, sponsored by Novartis Pharmaceuticals. Completed at 4 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-21.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the safety and tolerability of pasireotide LAR in combination with everolimus in advanced metastatic gastroenteropancreatic or pulmonary neuroendocrine Tumors (NET).

02

Conditions studied

  • Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System

Browse trials for

Keywords

  • Carcinoid tumor,
  • Gastroenteropancreatic Neuroendocrine Tumors,
  • Pulmonary Neuroendocrine Tumors,
  • pasireotide LAR,
  • SOM230 LAR,
  • everolimus,
  • RAD001,
  • Advanced Neuroendocrine Tumor,
  • Gastroenteropancreatic System
03

In context

Carcinoid Tumor

104 studies on the registry are indexed under Carcinoid Tumor; 11 are open to participants now.

This study's enrollment of 36 is below the median of 44 across 73 interventional studies indexed under Carcinoid Tumor.

Browse Carcinoid Tumor studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of grade 1/2 advanced pulmonary or gastroenteropancreatic neuroendocrine tumor
  • Progressive disease within last 12 months (only patients with nonfunctional tumors)
  • Documented liver
  • per determined by multiphase MRI or triphasic CT

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with radiolabeled somatostatin analogs within 12 months prior to reporting baseline symptoms
  • Previous treatment with mTOR inhibitors or pasireotide
  • Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study
  • Women who are pregnant or lactating

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Functional tumors, pre-treated

    Drug: Pasireotide LAR followed by Pasireotide LAR + Everolimus

  • Experimental
    Functional tumors, treatment naïve

    Drug: Pasireotide LAR followed by Pasireotide LAR + Everolimus

  • Experimental
    Nonfunctional tumors, pretreated 1

    Drug: Pasireotide LAR followed by Pasireotide LAR + Everolimus

  • Experimental
    Nonfunctional tumors, pretreated 2

    Drug: Everolimus followed by Pasireotide LAR + Everolimus

  • Experimental
    Nonfunctional tumors, treatment-naïve 1

    Drug: Pasireotide LAR followed by Pasireotide LAR + Everolimus

  • Experimental
    Nonfunctional tumors, treatment-naïve 2

    Drug: Everolimus followed by Pasireotide LAR + Everolimus

Interventions

  • DrugPasireotide LAR followed by Pasireotide LAR + Everolimus
  • DrugEverolimus followed by Pasireotide LAR + Everolimus
06

What researchers measure

Primary outcomes

  1. Evaluate safety and tolerability profile of pasireotide LAR in combination with everolimus in patients with advanced metastatic NET

    Time frame: 3 months

Secondary outcomes

  1. Evaluate safety and tolerability of pasireotide LAR and/or everolimus in patients with advanced metastatic NET

    Time frame: 15 months

  2. To assess pharmacokinetic exposures of pasireotide LAR and everolimus during monotherapy and in combination therapy

    Time frame: 15 months

  3. To assess potential drug-drug interactions between pasireotide and everolimus during combination therapy

    Time frame: 12 months

  4. To assess symptom control (bowel movements and flushing episodes) with pasireotide LAR in combination with everolimus in patients with functioning tumors

    Time frame: 15 months

  5. To assess the biochemical response (chromograninA, CgA) to pasireotide LAR in combination with everolimus

    Time frame: 15 months

07

Study locations

4 sites
  • Novartis Investigative Site
    Bad Berka, 99438, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Marburg, 35039, Germany
  • Novartis Investigative Site
    Muenster, 48149, Germany
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2010
First posted
Dec 20, 2010
Start
Nov 2010
Primary completionActual
Mar 2014
CompletionActual
Mar 2014
Last update
Dec 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01263353
Responsible party
Sponsor
First posted
Dec 20, 2010
Start date
Nov 2010
Primary completion
Mar 2014
Completion
Mar 2014
Last update
Dec 21, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion